Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-KRAS G12V mTCR PBL in Advanced Solid Tumors
NCT03190941Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2017
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 2 trial of anti-KRAS G12V murine TCR transduced PBL in pancreatic cancer (PC), gastric cancer (GC), gastrointestinal cancer, colon cancer, rectal cancer, sponsored by National Cancer Institute. Started Sep 2017; status: recruiting.
02
Drugs
anti-KRAS G12V murine TCR transduced PBL
03
Conditions
pancreatic cancer (PC)gastric cancer (GC)gastrointestinal cancercolon cancerrectal cancer
Beyond the preview
Go deeper on NCT03190941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190941.